Shots:  Associated with early onset and rapid progression of chronic kidney disease (CKD), APOL1 Mediated Kidney Disease dramatically affects people of African descent  AstraZeneca is developing AZD2373, the first potential precision treatment option for the treatment of AMKD with Ionis Pharmaceuticals. Recently, AZ shared promising data from the early P-I data from the MAD study …